amino acids; calcium chloride; dextrose; magnesium sulfate; potassium chloride; sodium acetate; sodium glycerophosphate; soybean oil · Fresenius Kabi Usa · NDA 200656
Perikabiven In Plastic Container
Earliest generic entry, as listed · earliest of 3 marketed strengths
3 May 2036
Blocked by patent: US 12390398.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12390398 | product | 3 May 2036 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 200656 · 001 · RLD | emulsion, intravenous | 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML) | 3 May 2036 |
| 200656 · 002 · RLD | emulsion, intravenous | 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1920ML) | 3 May 2036 |
| 200656 · 003 · RLD | emulsion, intravenous | 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML) | 3 May 2036 |